Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1977; 38(04): 0733-0741DOI: 10.1055/s-0038-1651894 Original Article Schattauer GmbH Bibliography of Sol Sherry Recommend Article Abstract Buy Article Full Text References A. Research Publications 1 The Vitamin C. Requirement of Man. Estimated after Prolonged Studies of the Plasma Concentration and Daily Excretion of Vitamin Cin 3 Adults on Controlled Diets. Ralli E. P, Friedman G. J, Sherry S. J. clin. Invest 1939; 18: 705. 2 Recovery of Vitamin C from the Human Bladder. Sherry S, Friedman G. J. Proc. Soc. exp. Biol. (N.Y.) 1939; 42: 707. 3 Effect of Insulin on Plasmin Level and Excretion of Vitamin C. Ralli E. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1940; 43: 669. 4 The Mechanism of the Excretion of Vitamin C by the Dog Kidney. Sherry S, Friedman G. J, Paley K, Berkman J, Ralli E. P. Amer. J. Physiol 1940; 130: 276. 5 The Mechanism of the Excretion of Vitamin C by the Human Kidney at Low and Normal Plasma Levels of Ascorbic Acid. Friedman G. J, Sherry S, Ralli E. P. J. Clin. Invest 1940; 19: 685. 6 Further Studies of the Effects of Insulin on Vitamin C Metabolism. Sherry S, Ralli E. P. J. clin. Invest 1948; 27: 217. 7 Presence and Significance of Desoxyribose Nucleoprotein in the Purulent Pleural Exudates of Patients. Sherry S, TiLLEtt W. S, Christensen L. R. Proc. Soc. exp. Biol. (N. Y.) 1948; 68: 179. 8 Streptococcal Desoxyribonuclease: Significance in Lysis of Purulent Exudates and Production by Strains of Hemolytic Streptococci. Tillet W. S, Sherry S, Christensen L. R. Proc. Soc. exp. Biol. (N. Y.) 1948; 68: 184. 9 The Effect in Patients of Streptococcal Fibrinolysin (Streptokinase) and Streptococcal Desoxyribonuclease on Fibrinous, Purulent and Sanguinous Pleural Exudations. Tillet W. S, Sherry S. J. clin. Invest 1949; 28: 173. 10 The Action of Streptococcal Desoxyribose Nuclease (Streptodornase) in vitro and Purulent Pleural Exudations of Patients. Sherry S, Johnson A, Tillett W. S. J. Clin. Invest 1949; 28: 1094. 11 Streptococcal Enzymatic Debridement. Tillett W. S, Sherry S, Christensen L. R, Johnson A, Hazlehurst G. Ann. Surg 1949; 131: 12. 12 Ultraviolet Photography of Paper Chromatograms in the Study of Nucleic Acids. Goeller J. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1950; 74: 381. 13 The Use of Streptokinase-Streptodornase in the Treatment of Hemothorax. Sherry S, Tillett W. S, Read C. T. J. thorac. Surg 1950; 20: 393. 14 The Extent of the Enzymatic Degradation Desoxyribonucleic Acid (DNA) in Purulent Exudates by Streptodornase. Sherry S, Goeller J. P. J. clin. Invest 1950; 29: 1588. 15 The Use of Streptokinase-Streptodornase in the Treatment of Post-Pneumonic Empyema. Tillett W. S, Sherry S, Read C. T. J. thorac. Surg 1951; 21: 275. 16 The Use of Streptokinase-Streptodornase in the Treatment of Chronic Empyema. Tillett W. S, Sherry S, Read C. T. J. thorac. Surg 1951; 21: 275. 17 The Low Potassium Syndrome Due to Defective Renal Tubular Mechanisms for Handling Potassium. Earle D. P, Sherry S, Eichna L. W, Conan Jr. N. Amer. J. Med 1951; 11: 283. 18 The Rationale of the Therapeutic Use of Streptokinase-Streptodornase in Amebic Abscess of the Liver. Sherry S, McCarty W. R, Tillett W. S. Arch. intern. Med 1951; 88: 752. 19 The Local Use of Streptokinase-Streptodornase in Chronic Refractory Areas of Suppuration with Draining Sinuses. Sherry S, Tillett W. S. Ann. Surg 1952; 135: 479. 20 Changes in Clot Retraction Time and Platelet Adhesiveness following Whole Body Irradiation. Savitsky J. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1954; 84: 587. 21 “Collagenase” Activity of Cathepsins. Sherry S, Troll W, Rosenblum E. D. Proc. Soc. exp. Biol. (N.Y.) 1954; 87: 125. 22 The Action of Plasmin on Synthetic Substrates. Troll W, Sherry S, Wachman J. J. biol. Chem 1954; 208: 85. 23 The Action of Thrombin on Synthetic Substrates. Sherry S, Troll W. J. biol. Chem 1954; 208: 95. 24 The Fibrinolytic Activity of Streptokinase Activated Human Plasmin. Sherry S. J. clin. Invest 1954; 33: 1054. 25 The Enzymatic Dissolution of Experimental Intervascular Thrombi in the Dog by Trypsin, Chemotrypsin and Plasminogen Activators. Sherry S, Titchener A, Gottesman L, Wasserman P, Troll W. J. clin. Invest 1954; 33: 1303. 26 Assay of Plasma Prothrombin with a Synthetic Substrate. Glueck H. I, Sherry S, Troll W. Proc. Soc. exp. Biol. (N. Y.) 1954; 87: 646. 27 The Activation of Human Plasminogen by Streptokinase. Troll W, Sherry S. J. biol. Chem 1954; 213: 881. 28 Prevention of Post-operative Adhesions in the Dog by Intravenous Injections of Plasminogen Activators. Sherry S, Callaway D, Freiberg R. Proc. Soc. exp. Biol. (N.Y.) 1955; 90: 1. 29 Serum Transaminase. Observations in a large group of patients. Chinsky M, Shmagronoff G, Sherry S. J. Lab. clin. Med 1956; 47: 108. 30 Some Effects of Orinase in the Rat. Lang S, Sherry S. Metabolism 1956; 5: 733. 31 Experience with Orinase in the Management of Adult Diabetes. Braverman A. E, Drey N. W, Sherry S. Metabolism 1956; 5: 911. 32 Serum Transaminase. A Comparison of the Serum Oxalacetic and Pyruvic Transaminase. Chinsky M, Wolff R. J, Sherry S. Amer. J. med. Sci 1957; 233: 400. 33 The Use of Tolbutamide in the Management of Adult Diabetes. Sherry S, Zeffren J. L, Braverman A. E, Drey N. Ann. N. Y. Acad, of Sciences 1957; 71: 249. 34 An Approach to Intravascular Fibrinolysis in Man. Sherry S, Fletcher A. P, ALKJaeRSiG N, Smyrniotis F. E. Trans. Ass. Amer. Phycns 1975; 70: 288. 35 The Effects of Prolonged Tolbutamide Therapy on the Hepatic Function and Serum Cholesterol of Adult Diabetic Patients. Zeffren J. L, Sherry S. Metabolism 1957; 6: 504. 36 The Activation of Human Plasminogen. 1. Spontaneous Activation in Glycerol. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1958; 233: 81. 37 The Activation of Human Plasminogen. 2. A Kinetic Study of Activation with Trypsin, Urokinase and Streptokinase. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1958; 233: 86. 38 Physicochemical Studies on Human Plasminogen (Profibrinolysin) and Plasmin (Fibrinolysin). Shulman S, Alkjaersig N, Sherry S. J. biol. Chem 1958; 233: 91. 39 Clearance of Heterologous Protein from the Circulation of Normal and Immunized Man. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1958; 37: 1306. 40 The Treatment of Patients Suffering from Early Myocardial Infarction with Massive and Prolonged Streptokinase Therapy. Fletcher A. P, Alkjaersig N, Smyrniotis F. E, Sherry S. Trans. Ass. Amer. Phycns 1958; 71: 278. 41 Epsilon-Aminocaproic Acid: An Inhibitor of Plasminogen Activation. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1959; 234: 832. 42 Urokinase Excretion in Health and its Alterations in Certain Disease States. Smyrniotis F, Fletcher A. P, Alkjaersig N, Sherry S. Thrombosis et Diathesis Haemorrhagica 1959; 3: 257. 43 Studies on Enhanced Fibrinolytic Activity in Man. Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. J. clin. Invest 1959; 38: 810. 44 The Fibrinolysin System: Some Physiological Considerations. Sherry S, Fletcher A. P, Alkjaersig N. Conn. Tissues, Thrombosis and Atherosclerosis. Edited by Page I. Academic Press; 1959: 1959. 45 The Mechanism of Clot Dissolution by Plasmin. Alkjaersig N, Fletcher A. P, Sherry S. J. clin. Invest 1959; 38: 1086. 46 The Maintenance of a Sustained Thrombolytic State in Man., I. Induction and Effects. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1959; 38: 1096. 47 The Maintenance of a Sustained Thrombolytic State in Man. II. Clinical Observations on Patients with Myocardial Infarction and Other Thromboembolic Disorders. Fletcher A. P, Sherry S, Alkjaersig N, Smyrniotis F. E, Jick S. J. clin. Invest 1959; 33: 1111. 48 Epsilon-Aminocaproic Acid, “A Potent Antifibrinolytic Agent”. Sherry S, Fletcher A. P, Alkjaersig N, Sawyer W. D. Trans. Ass. Amer. Phycns 1959; 72: 62. 49 Studies on the Thrombolytic Activity of Human Plasma. Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1960; 39: 426. 50 Evaluation of Human Fibrinolysin (Actase). Fletcher A. P, Alkjaersig N, Sawyer W. D, Sherry S. J. Amer. med. Ass 1960; 172: 912. 51 Comparison of Fibrinolytic and Fibrinogenolytic Effects of Plasminogen Activators and Proteolytic Enzymes in Plasma. Sawyer W. D, Alkjaersig N, Fletcher A. P, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1960; 5: 149. 52 The Assay of Thrombolytic (Fibrinolytic) Mixtures Intend for Therapeutic Use. Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1961; 57: 620. 53 Impairment of Hemostasis in the Urinary Tract: The Role of Urokinase. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1961; 58: 34. 54 The Use of Epsilon-Aminocapronic Acid, A Potent Inhibitor of Fibrinolytic Activity, in the Management of Postoperative Hematuria. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Urol. (Baltimore) 1961; 86: 829. 55 Plasma Amino Acid Chromatography with Ion Exchange Resin Loaded Paper: Assay of Epsilon Aminocaproic Acid (EACA). McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1962; 59: 1. 56 The Absorption, Distribution and Excretion of Epsilon-Aminocaproic Acid (EACA) Following its Oral or Intravenous Administration to Man. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1962; 59: 15. 57 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. I. The Significance of Fibrinogen Proteolyses and Circulating Fibrinogen Breakdown Products. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1962; 41: 896. 58 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. II. The Significance Mechanism and Consequences of Defective Fibrin Polymerization. Alkjaersig N, Fletcher A. P, Sherry S. J. clin. Invest 1962; 41: 917. 59 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. III. Demonstration of Abnormal Clot Structure by Electron Microscopy. Bang N. U, Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1962; 41: 935. 60 Influence of pH, Ionic Strength, Neutral Ions and Thrombin on Fibrin Polymerization. Latallo Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Amer. J. Physiol 1962; 202: 681. 61 Inhibition of Fibrin Polymerization by Fibrinogen Proteolysis Products. Latello Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Amer. J. Physiol 1962; 202: 681. 62 Altered Fibrinolytic Mechanism in Hepatic Cirrhosis and its Potential Clinical Significance. Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. Trans. Ass. Amer. Phycns 1963; 76: 280. 63 Abnormal Plasminogen-Plasmin System Activity (“Fibrinolysis”) in Patients with Hepatic Cirrhosis: Its Cause and Consequences. Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. J. clin. Invest 1964; 43: 681. 64 Assay of Urokinase Preparations with the Synthetic Substrate, Acetyl-1-lysine Methyl Ester. Sherry S, Alkjaersig N, Fletcher A. P. J. Lab. clin. Med 1964; 64: 145. 65 The Assay of Plasma Thrombolytic Activity Using Fluorescein Labeled Clots. Genton E, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1964; 64: 313. 66 The Purification and Properties of Plasminogen Activator from Pig Heart. Bachmann F, Alkjaersig N, Fletcher A. P, Sherry S. Biochemistry 1964; 3: 1578. 67 The Development of Urokinase as a Thrombolytic Agent. Maintenance of a Sustained Thrombolytic State in Man by its Intravenous Infusion. Fletcher A. P, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. J. Lab. clin. Med 1965; 65: 713. 68 The Assay of Urokinase Preparations for Contamination with Thromboplastic Moieties. Alkjaersig N, Fletcher A. P, Sherry S. J. Lab. clin. Med 1965; 65: 732. 69 The Effect of Fibrin and Fibrinogen Proteolysis Products on Clot Physical Properties. Hirsh J, Fletcher A. P, Sherry S. Amer. J. Physiol 1965; 209: 415. 70 Comparative Activity of Thrombin on Substituted Arginine and Lysine Esters. Sherry S, Alkjaersig N, Fletcher A. P. Amer. J. Physiol 1965; 209: 577. 71 Activity of Plasmin and SK-Activator on Substituted Arginine and Lysine Esters. Sherry S, Alkjaersig N, Fletcher A. P. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 16: 19. 72 Observations on the Spontaneous Arginine and Lysine Esterase Activity of Human Plasma, and their Relation to Hageman Factor. Sherry S, Alkjaersig N, Fletcher A. P. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; Supplement 20: 243. 73 The Preparation and Properties of Human Fibrinogen of Relatively High Solubility. Mosesson M. W, Sherry S. Biochemistry 1966; 5: 2829. 74 The Proteolysis of Fibrinogen by Plasmin: The Identification of Thrombin Clottable Fibrinogen Derivatives which Polymerize Abnormally. Fletcher A. P, Alkjaersig N, Fisher S, Sherry S. J. Lab. clin. Med 1966; 68: 780. 75 The Enzymatic Lysis of Plasma Clots: The Influence of Fibrin Stabilization on Lysis Rates. Gormsen J, Fletcher A. P, Alkjaersig N, Sherry S. Arch, of Biochem. and Biophys 1967; 120: 654. 76 Human Fibrinogen of Relatively High Solubility: Comparative Biophysical, Biochemical and Biological Studies with Fibrinogen of Lower Solubility. Mosesson M. W, Alkjaersig N, Sweet B, Sherry S. Biochemistry 1967; 6: 3279. 77 Immunoelectrophoretic Characterization of Plasma Fibrinogen Derivatives in Patients with Pathological Plasma Proteolysis. Fisher S, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1967; 70: 903. 78 Studies of a Chronic Intravascular Coagulation Syndrome associated with plasma Cryoprecipitate (“Cryofibrinogen”) preceeding the appearance of Primary Ovarian Carcinoma. Mosesson M. W, Colman R, Sherry S. New Engl. J. Med 1968; 278: 815. 79 The Effect of Urokinase Antiserum on Plasminogen Activators: Demonstration of Immunologic Dissimilarity between Plasma Plasminogen Activator and Urokinase. Kucinski C, Fletcher A. P, Sherry S. J. clin. Invest 1968; 47: 1238. 80 Observations on the Plasma Kallikreinogen-Kallikrein Enzyme System. Sherry S, Colman R. W. Trans. Ass. Amer. Phycns 1968; 81: 40. 81 Studies on the Kallikreinogen-Kallikrein Enzyme System of Human. Plasma. I. Isolation and Purification of Plasma Kallikreins. Colman R. W, Mattler L, Sherry S. J. clin. Invest 1969; 48: 11. 82 Studies on the Kallikreinogen-Kallikrein Enzyme System of Human Plasma. II. Identification of the Kaolin Activated Arginine Esterase as Plasma Kallikrein. Colman R. W, Mattler L, Sherry S. J. clin. Invest 1969; 48: 23. 83 The Kallikreinogen-Kallikrein Enzyme System of Human Plasma. Assay of Compenents and Preliminary Observations in Disease States. Colman R. W, Mason J. W, Sherry S. Ann. intern. Med 1969; 71: 763. 84 Isolation and Characterization of Clottable Low Molecular Weight Fibrinogen Derived by Limited Plasmin Hydrolysis of Human Fraction I-4. Sherman L. A, Mosesson M. W, Sherry S. Biochemistry 1969; 8: 1515. 85 In Vivo Transformation between Fibrinogen of Varying Ethanol Solubilities: A First Step in Fibrinogen Catabolism. Sherman L. A, Fletcher A. P, Sherry S. J. Lab. clin. Med 1969; 73: 574. 86 The Purification of Fibrinogen Degradation Products by Pevikon Block Electrophoresis. Marder V. J, James H. L, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1969; 22: 234. 87 The Urokinase-Pulmonary Embolism Trial. Phase I. Results. Urokinase-Pulmonary Embolism Trial Study Group. J. Amer. med. Ass 1970; 214: 2163. 88 Detection of Serum Fibrinogen and Fibrin Degradation Products. Comparison of Six Techniques using Purified Products and Application in Clinical Studies. Marder V. J, Matchett M. O, Sherry S. Amer. J. Med 1971; 51: 71. 89 Urokinase-Streptkokinase Pulmonary Embolism Trial. Phase II Results. A National Cooperative Trial. J. Amer. med. Ass 1974; 229: 1606. 90 Platelet Coagulant Activities and Venous Thrombosis After Hip Surgery. Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E, Sherry S. Trans. Ass. Amer. Phycns 1974; 89: 140-149. 91 Effect of Plasmic Degradation Products of Fibrinogen on the Radioimmunoassay of Human Fibrinopeptide A. Budzynski A. Z, Marder V. J, Sherry S. Blood 1975; 45: 757-768. 92 The Relationship of Platelet Coagulant Activities to Venous Thrombosis Following Hip Surgery. Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E. S, Sherry S. Brit. J. Haemat 32: 421-436 1976; B. Review Articles 1 Adult Scurvy and the Metabolism of Vitamin C. Ralli E. P, Sherry S. Medicine 1941; 20: 251. 2 Thrombin as a Proteolytic Enzyme. Sherry S, Toll W, Glueck H. Physiol. Rev 1954; 34: 736. 3 Fibrinolysis and Fibrinolytic Activity in Man. Sherry S, Fletcher A. P, Alkjaersig N. Physiol. Rev 1959; 39: 343. 4 Proteolytic Enzymes: A Therapeutic Evaluation. Sherry S, Fletcher A. P. Clin. Pharm & Therap 1960; 1: 202. 5 Thrombolytic Agents. Fletcher A. P, Sherry S. Ann. Rev. Pharmacol 1966; 6: 89. 6 Fibrinolysis. Sherry S. Ann. Rev. Med 1968; 19: 247. 7 Current Status of Antithrombotic Therapy in Cardiovascular Disease. Rogers P, Sherry S. Progr. cardiovasc. Dis 1976; 79: 235-253. C. Editorials 1 Thrombolytic Therapy. Sherry S, Fletcher A. P. Amer. Heart J 1961; 61: 575. 2 Requirements of an Ideal Thrombolytic Agent. Unsigned. J. Amer. med. Ass 1960; 172: 944. 3 Urokinase. Unsigned. New Engl. J. Med 1969; 277: 1203. 4 Urokinase-Pulmonary Embolism Study. Walsh P. N, Stengle J. M, Sherry S. Circulation 1969; 39: 153. 5 Streptokinase. Sherry S. New Engl. J. Med 1969; 280: 723. 6 Thrombolysis by Urokinase. Sherry S. J. Atheroscler. Res 1969; 9: 3. 7 Thrombosis. Sherry S. Circulation 1969; 40: 755. 8 Treatment of Pulmonary Embolism with Urokinase. Results of a Clinical Trial (Phase D). Hyers T, Stengle J. M, Sherry S. Circulation 1970; 42: 979. 9 Streptokinase Therapy for Thrombo-occlusive Vascular Disease. Sherry S. Ann. intern. Med 1971; 74: 437. 10 Thrombus Prevention. Sherry S. New Engl. J. Med 1971; 284: 1324. 11 Low dose heparin prophylaxis for post-operative venous thrombi-embolism. Sherry S. New Engl. J. Med 1975; 293: 300-302. 12 Low dose heparin for the prophylaxis of pulmonary embolism. Sherry S. Amer. Rev. resp. Dis 114: 661-666 1976; D. Chapter and Articles in Books and Monographs 1 Dynamics of Thrombosis. Sherry S. In Cerebral Vascular Diseases. Trans. Third Conf. Ed. Millikan C. H, Siekert R. G, Whisnant J. P. Grune & Stratton; N.Y.: 1961: 60. 2 Rationale Limitations of the Use of Thrombolytic (Fibrinolytic) Agents in the Treatment of Thromboembolic Disease. Sherry S, Fletcher A. P, Alkjaersig N. Progress in Hematology. Edited by Tocantins L. M. Vol. III. Grune & Stratton; N.Y.: 1962: 244. 3 Sections of Pulmonary Embolism and Infarction; Fat Embolism; and Pulmonary Hemorrhage. Sherry S. In Cecil and Loeb’s Textbook of Medicine. 11th Edition.. W. B. Saunders Company; Philadelphia: 1963: 560-568. 4 Assays for Fibrinolytic Enzymes Based on the Use of Synthetic Substrates. Sherry S, Alkjaersig N, Fletcher A. P. in Blood Coagulation, Hemorrhage and Thrombosis. Methods of Study. Ed. Tocantins L. M, Kazal L. A. Grune & Stratton; N.Y.: 1964: 277. 5 The “Ideal” Anticoagulant Drug. Sherry S. in Cardiovascular Drug Therapy (Hahnemann Symposium). Likoff E. W, Moyer J. H. Grune & Stratton; N. Y.; 1965. Chapter 37 235-239. 6 Fibrinolytic Therapie: Current and Future Clinical Status. Sherry S. in Cardiovascular Drug Therapy (Hahnemann Symposium). Ed. Likoff W, Moyer J. H. Grune & Stratton; N. Y.: 1965. Chapter 38 261-265. 7 Sections on Pulmonary Embolism and Infarction; Fat Embolism; Pulmonary Hemorrhage; and Fibrinolysis and Fibrinolytic Disorders. Sherry S. In: Cecil and Loeb’s Textbook of Medidne. 12th Edition.. W. B. Saunders Company; Philadelphia: 1967: 534-541 1136–1138. 8 Thrombolytic Therapy in Acute Myocardial Infarction. Fletcher A. P, Sherry S. in Symposium on Coronary Heart Disease. 95 Ed. Blumgart H. L. American Heart Association Monograph No. 2 Am. Heart Assoc.; N. Y.: 1968 9 Fibrinolysis and Thrombosis. Sherry S. In Thrombosis. Ed. Sherry S, Genton E, Brinkhous K. M, Stengle J. M. National Academy of Sciences; Washington, D.C.: 1969: 585-608. 10 Section on Thromboembolic Diseases. Sherry S. In Cecil-Loeb’s Textbook of Medicine, 13th Edition. Ed. Beeson P. B, McDermott W. W. B. Saunders Co.; Philadelphia: 1971: 1040-1050. 11 Mechanisms of Fibrinolysis. Sherry S. In Hematology. Ed. Williams W. J, Beutler E, Erslev A. J, Rundles R. W. Blakiston Division, McGraw-Hill Book Co.; 1972. Chapter 134 1105-1114. 12 Fibrinolysis. Marder V, Sherry S. In Pathophysiology–Altered Regulatory Mechanisms. Ed. Frohlich E. J. B. Lippincott Co.; Philadelphia: 1972. Chapter 26 547-564 2nd Edition. in press. 13 Priorities in Cardiovascular Research: Prevention of Coronary Artery Thrombosis. Sherry S. In Changing Concepts in Cardiovascular Disease. Russek E. H. I, Zohmann B. L. Williams & Wilkins; Baltimore: 1972: 300-306. 14 Thrombolysis for Acute Myocardial Infarction. Sherry S. In Atherosclerosis and Coronary Heart Disease. Ed. Likoff W, Segal B. L, Insull W, Moyer J. H. Grune & Stratton; N. Y.: 1972: 426-430. 15 Is Thrombolytic Therapy Justified. Sherry S. In Thromboembolism: Diagnosis and Treatment. Ed. Kakkar V. V, Jouhar A. J. Churchill Livingstone; Edinburgh and London: 1972: 144-153. 16 Anticoagulants, Platelet Aggregation in Inhibitors and Fibrinolysis. Sherry S. In: Paul D. White Symposium: Major Advances in Cardiovascular Therapy. Ed. Russek H. I, Zohman B. L. Williams & Wilkins; Baltimore: In Press. 17 Current Developments in Thrombolytic Therapy. Sherry S. In Present Status of Thrombosis. Its Pathophysiology, Diagnosis and Treatment. Ed.: Losito R. F. K. Schattauer Verlag; Stuttgart, New York: 1973: 201-210. 18 Current Status of Urokinase Therapy. Sherry S. In Pulmonary Thromboembolism. Ed.: Moser K. M, Stein M. Yearbook Publishers, Inc.; 1973: 280-288. 19 Detection of Thrombi. Sherry S. In Diagnostic Nuclear Cardiology. Ed. Patt P, Strauss H. W, James A. E. C. V. Mosby; St. Louis.: 20 Thrombo-embolic Diseases. Sherry S. In: Cecil-Loebs Textbook of Medicine. 14th Edition.. Beeson P. B, McDermott W. Eds. W. B. Saunders, Co.; Phila.: 1975: 910-921. 21 Fibrinolysis. Marder V. J, Sherry S. In: Pathophysiology-altered Regulatory Mechanisms. 2nd Edition.. Friohlich E. Ed. J. B. Lippincott; Cot., Phila.: (In press). 22 Pulmonary Embolism and Infarction. Sherry S. In: “Cardiac Emergency Care”. Chung E. K. Ed. Lea and Febinger; Phila.: 1975: 17-33. 23 Present Status of Antithrombotic Therapy in Acute Heart Attack. Sherry S. In: “The Myocardium: Failure and Infarction”. Braunwald E. Ed. H. P. Publishing Co.; N. Y.: 317-327 1974 24 Altered Coagulability in Tumor Patients. Sherry S. in Paraneoplastic Syndromes. Ed. Hall T. C. N.Y. Academy of Sciences; N. Y.: 1974: 251 294—296. 25 Mechanisms of Fibrinolysis. Sherry S. In Hematology. 2nd Edition. Ed. Williams W. J, Beutler E, Erslev A. J, Rundles R. W. Blakiston Division, McGraw-Hill Book Co.; 1976. Chapter 138. 26 The Role of the Platelet in Thrombosis. Sherry S. In: “Platelets and Thrombosis”. Mills D. C. B, Pareti F. I. Eds. Academic Press; In press. 27 Therapeutic Thrombolysis: Past, Present and Future. In: “Urokinase and Thrombosis”. Paoeletti R, Sherry S. Eds. Academic Press; In press. 28 Foreword. Sherry S. In: Heparin, Chemistry and Clinical Use. Kakkar V. V, Thomas D. P. Ed. Academic Press; London: 1976 E. Books and Monographs 1 Thrombosis. Edited by Sherry S, Genton E, Brinkhous K. M, Stengle J. M. National Academy of Sciences; Washington, D. C.: 1969: 762. 2 Immunological Mechanisms in Blood Coagulation, Thrombosis and Hemostasis. New Development in Antithrombotic Therapy. Ed: Duckert F, Brinkhous K. M, Hinnom S, Koller F, Sherry S, Stengle J. M. Thrombos. Diathes. haemorrh. (Stuttg.). Suppl. 45. 1971 3 The Epidemiology of Venous Thrombosis. Ed: Foster C. S, Genton E, Henderson M, Sherry S, Wessler S. Milbank Memorial Fund Quarterly 10 (01) Part 2: 9-289 1972; 4 Thrombosis: Risk Factors and Diagnostic Approaches. Ed: Brinkhous K. M, Owren P. A, Hinnom S, Surgenor D. M, Sherry S, Stengle J. M. Thrombos. Diathes. haemorrh. (Stuttg.) (Suppl. 51) 1972; 1-388. 5 The Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Ed: Sasahara A. A, Hyers T, Cole C, Ederer F, Murray J. A, Wenger N. K, Sherry S, Stengle J. M. Circulation 47 Suppl. II 1-108 1973; 6 Thrombosis: Mechanisms and Control. Ed: Brinkhous K. M, Surgenor D, Hinnom S, Sherry S, Stengle J. M. Thromb. Diathes. haemorrh. (Stuttg.) (Suppl. 54) 1937; 1-464. 7 Platelets and Thrombosis. Ed: Sherry S, Scriabine A. University Park Press; Baltimore: 332 1974 8 Urokinase and Thrombosis. Ed: Paoletti R, Sherry S. Academic Press; In press. F. Other Publications 1 Typhus in Lower Bavaria. Sherry S. The Bulletin, U.S. Army Medical Dept 1946; 5: 141. 2 The Action of Streptococcal Desoxyribonuclease on Purulent Exudates. Sherry S. Trans. N. Y. Acad. Sc 1952; 14: 138. 3 Current Concepts of Diabetes. Sherry S. Bull. N. Y. Acad. of Med 1953; 29: 202. 4 Serum Transaminase as a Diagnostic Aid. Chinsky M, Sherry S. A.M.A. Arch. Int. Med 1957; 99: 556. 5 Biochemical, Experimental and Clinical Studies with Proteolytic Enzymes (with Particular Reference to the Fibrinolytic Enzyme of Human Plasma). Sherry S, Alkjaersig N. Ann. N. Y. Acad of Sciences 1957; 63: 52. 6 Studies on the Fibrinolytic Enzyme of Human Plasma. Sherry S, Alkjaersig N. Thrombos. Diathes. haemorrh. (Stuttg.) 1957; 1: 264. 7 Possibilities for Therapy with Enzymes. Sherry S. Ann. Otol. (St. Louis) 1959; 68: 34. 8 Developments in Fibrinolytic Therapy for Thromboembolic Disease. Sherry S, Fletcher A. P, Alkjaersig N. Ann. intern. Med 1959; 50: 560. 9 Thrombolytic Therapy for Coronary Heart Disease. Fletcher A. P, Sherry S. Circulation 1960; 22: 619. 10 Thrombolytic Therapy: Basic and Therapeutic Considerations. Sawyer W. D, Alkjaersig N, Fletcher A. P, Sherry S. Arch. intern. Med 1961; 107: 274. 11 Hemostatic Mechanisms and Proteolysis in Shock. Sherry S. In Symposium on Shock. Federation Proceedings 1961; 20 (02) Part III (Suppl. 09) 209. 12 Thrombolytic Therapy. Sherry S. South Med. J 1961; 54: 1287. 13 Status of Therapy: Critique and Outlook for the Future. Sherry S. In Thrombolytic Activity and Related Phenomena. Ed. Koller F. Thrombos. Diathes. haemorrh. (Stuttg.) 1962; 6 (Suppl. 01) 344. 14 Introduction to Symposium on Thrombosis and Anticoagulation. Sherry S. (Guest Editor) Amer. J. Med 1962; 33: 619. 15 Fibrinolytic Mechanisms and the Development of Thrombolytic Therapy. Fletcher A. P, Aikjaersig N, Sherry S. Amer. J. Med 1962; 33: 738. 16 Role of Fibrinolysin Therapy in the Treatment of Acute Myocardial Infarction. Sherry S, Letcher A. P. In Coronary Heart Disease (7th Hahnemann Symposium). Ed. Likoff W, Moyer J. H. Grune & Stratton; N.Y.: 1963: 383. 17 Fibrinolytic Bleeding and its Management. Sherry S, Alkjaersig N, Fletcher A. P. Ann. N.Y. Academy of Sciences 1964; 115 (01) 481. 18 Fibrinolytic Bleeding and its Control. Sherry S, Fletcher A. P, Alkjaersig N. Annotation. Amer. Heart J 1964; 67: 425. 19 Current Status of Thrombolytic Therapy. Sherry S. Geriatrics 1964; 19: 628. 20 Fibrinolysis. Sherry S, Fletcher A. P, Alkjaersig N. Physiology for Physicians. 1964 2. No. 4. 21 Thromboembolic Disorders. Sherry S, Fletcher A. P, Wessler S. Nat. Conf. Cardiov. Dis 1964; 2: 585. 22 Present Concept of the Fibrinolytic System. Sherry S. Series Haematologica, Scand. J. of Haem 1965; 7: 70. 23 Current Concepts of the Relationship of Thrombosis and Thrombolysis. Sherry S. Ass. Res. nerv. Dis. Proc 1966; 41: 349. 24 Fibrinolysis and Afibrinogenemia. Sherry S. Anaesthesiology 1966; 27: 465. 25 Perspectives: Fibrinolysis and Thrombolysis. Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; Supplement 20: 1. 26 Fibrinolytic Mechanisms in Tissue Injury. Sherry S. Gastroenterology 1966; 51: 901. 27 Acute Pulmonary Embolism. Sherry S. Geriatrics 1967; 22: 150. 28 Urokinase. Sherry S. Ann. intern. Med 1968; 69: 415. 29 Fibrinolytic Agents. Sherry S. Disease-a-Month. Year Book Publishers, Inc.; May 1969. Chicago: 1-32. 30 Therapeutic Experiences with Urokinase. In Therapeutische and Experimentelle Fibrinolyse. Proceedings of International Symposion. Oct. 1967 in Ulm (Donau). Thrombos. Diathes. haemorrh. (Stuttg.) 1969; Suppl. 32: 373. 31 The Kallikrein System: A Basic Defense Mechanism. Sherry S. Hospital Practice 5: 75 1970; 32 Current Status of Fibrinogen and Fibrin Degradation Products. Sherry S. Thrombos. Diathes. haemorrh (Stuttg.) 1970; Suppl. 39: 169. 33 Reports of Subcommittee on Fibrinolysis and Thrombolysis, International Committee on Haemostasis and Thrombosis. Sherry S. Thrombos. Diathes. haemorrh. (Stuttg) Suppl. 26: 457 1968; Suppl. 35: 181, 1969; Suppl. 39: 453; Suppl. 45: 347, 1971; Suppl. 51, 1972. 34 Reaction of Fibrinogen Digests and Purified Fibrinogen Degradation Products in the TRCHII and Staphylococcal Clumping Tests. Application in Clinical Studies. Marder V. J, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 367-372 1971; 35 Immunologic Techniques for the Identification of Fibrinogen Derivatives Produced by Enzymatic and Chemical Degradation. Marder V. J, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 269-279 1971; 36 The Present Status of Urokinase Trial. Sherry S. for the Urokinase-Pulmonary Embolism Trial Study Group. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 9-21 1971; 37 Prospects in Antithrombotic Therapy. Sherry S. Amer. J. Cardiol 29: 81 1972; 38 Thrombolytic Therapy for Acute Myocardial Infarction. Sherry S. Amer. Heart J 1972; 83: 427-430. 39 Present Status of Antithrombotic Therapy in Acute Heart Attack. Sherry S. Hospital Practice 7: 45-54 1972; 40 Clinical Trials with Antithrombotic and Thrombolytic Agents. Sherry S. Principles and Pitfalls Thrombos Diathes. haemorrh. (Stuttg.) 29: 1-10 1973; 41 Trial and Error; Questions and Answers. Sherry S. Transactions of the Plenary Sessions, IV International Congress on Thrombosis and Haemostasis. Ed.: Deutsch E, Lechner K, Brinkhous K, Hinnon S. F. K. Schattauer Verlag; Stuttgart: 263-270 1974 42 Coronary Thrombosis in Myocardial Infarction. Chandler A. B, Chapman I, Erbarmt L, Roberts W. C, Schwartz C. J, Sinapius D, Spain D. M, Sherry S, Ness P, Simmon T. L. Amer. J. Cardiol 34: 824-833 1974; 43 Urokinase-streptokinase Pulmonary Embolism Trial. (Phase II Results). Bell W, Simon T. L, Stengle J. M, Sherry S. Circulation 50: 1070-1071 1974; 44 Urokinase in Thrombo-embolic Disease: Pulmonary Embolism. Sasahara A. A, Stengle J. M, Sherry S. Amer. Heart J 89: 403-404 1975; 45 Diagnostic Developments in Thrombotic Disease. Sherry S. Cardiovascular Diseases Bulletin of the Texas Heart Institute 2: 59-63 1975; 46 William Smith Tillett. 1892–1974. Sherry S. Trans. Ass. Amer. Phycns 88: 32-34 1975; 47 The Phase II Urokinase-Streptokinase Pulmonary Embolism Trial – A National Cooperative Study. Sasahara A. A, Bell W. R, Simon T. L, Stengle J. M, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 33: 464-476 1975; 48 Therapy of Deep Vein Thrombosis and Pulmonary Embolism. Medical Approach. Sherry S. in Prophylactic Therapy of Deep Vein Thrombosis and Pulmonary Embolism. Ed. Fratantoni J, Wessler S. DHEW Publication No (NIH) 76–866 US Department of Health, Education and Welfare; Washington, DC: 127-136 1975 49 Prevention of pulmonary embolism with low-dose heparin. Sherry S. Postgrad, med. J 59: 80-84 1976; 50 Interrelationships between platelets and coagulation in the pathogenesis of venous thrombosis. Sherry S. S. Afr. med. J 50: 425-427 1976; 51 Anticoagulant therapy: Questions and answers. Sherry S. Comprehensive Therapy. In press. 52 Thrombo-embolism. Sherry S. Proc. Chicago Inst, of Med. In press.
